High sensitivity C-reactive protein (hsCRP) level in cerebrovascular accident (Stroke)

Journal, Indian Academy of Clinical Medicine

Volumn 11, Issue 3, 2010, Pages 204-207

  Mishra, Pinky Talreja ^a   Chandra, Rakesh ^a   Saxena, S K ^a   Verma, Sanjay ^a   Jain, Renu ^b   Bhuyan, Ashok ^a  

^a Department of Medicine ^*

^b GSVM MEDICAL COLLEGE   (India)

Author keywords

Haemorrhagic stroke; hsCRP level; Ischaemic stroke

Indexed keywords

C REACTIVE PROTEIN; HIGH SENSITIVITY C REACTIVE PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ANESTHESIA (SENSORY DYSFUNCTION); ARTICLE; BRAIN INFARCTION; CEREBROVASCULAR ACCIDENT; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIABETES MELLITUS; DYSLIPIDEMIA; FACIAL NERVE PARALYSIS; FEMALE; HEMIANAESTHESIA; HEMIPARESIS; HEMORRHAGIC BRAIN INFARCTION; HUMAN; ISCHEMIC BRAIN INFARCTION; MALE; PROGNOSIS; RISK FACTOR; STATISTICAL SIGNIFICANCE; SYMPTOM;

EID: 79551579761     PISSN: 09723560     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Pearson TA, Mensah GA, Alexander RW. Marker of inflammation and cardiovascular diseases: application to clinical and public health practice. A statement for healthcare profession from the Centres for Disease Control and Prevention and the American Heart Association. Circulation 2003; 107: 499-511.
2. Ridker PM, Buring JE, Shih J. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation 1998; 98 (8): 731-3.
3. Ridker PM, Rifai N, Rose L. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002; 347 (20): 1557-65.
4. Ridker PM, Cushman M, Stampfer MJ. Inflammation, aspirin and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997; 336 (14): 973-9.
5. Rost NS, Wolf PA, Kase CS et al. Plasma concentration of Creactive protein and risk of ischaemic stroke and transient ischaemic attack: the Framingham study. Stroke 2001; 32 (11): 2575-9.
6. Bamford J, Sandercock PAG, Dennis M et al. Classification of natural history of clinical identifiable subtypes of cerebral infarction. Lancet 1991; 337: 1521.
7. Kannel, McGreen. Diabetes most common risk factor. Arch Inern Med 1979; 54: 312-424.
8. Benson RT, Sacco RL. Stroke prevention: hypertension, diabetes, tobacco, and lipids. Neurol Clin 2000; 18 (2): 309-19.
9. Di Napoli M, Papa F, Bocola V. C-reactive protein in ischaemic stroke: an independent prognostic factor. Stroke 2001; 32: 917-24.
10. Arenillas JF, Alvarez-Sabin J, Molina CA. C-reactive protein predicts further ischaemic events in first transient ischaemic attack or stroke patients with intracranial large artery occlusive disease. Stroke 2003; 34 (10): 2463-8.
11. Yoshiyuki Wakugawa, Yutaka Kiyohara, Yumihiro Tanizaki et al. C-reactive protein and risk of first ever ischaemic and haemorrhagic stroke in a general Japanese population. Stroke 2006; 37: 27-32.
12. Guo Y, Jiang X, Chen S et al. C-reactive protein as an important prognostic marker for ischaemic stroke. Zhonghua Yu Fang Yi Xue Za Zhi 2003; 37: 102-4.
13. Kerstin Winbeck, Hogler Poppert, Thorleif Etgen et al. Prognostic relevance of early serial C-reactive protein measurements after first ischaemic stroke. Stroke 2002; 33: 2459-64.
14. Mitchell SV Elkind, Wanling Tai, Kristen Coates et al. High- Sensitivity C-Reactive Protein, Lipoprotein-Associated Phospholipase A2, and Outcome After Ischaemic Stroke. Arch Intern Med 2006; 166: 2073-80.